Skip to main content

Table 1 Clinical and pathological features of 8 cases with GP

From: Gliomatosis peritonei: a series of eight cases and review of the literature

case

Age, y

CA125 U/ml

Tumor Size (cm)

Surgical Procedure (1st surgery)

Primary tumor

Metastatic Tissue of the 1st surgery

Adjuvant therapy

GFAP

Residual GP

Outcome

1

23

420.1

18

USO, Peritonectomies, Appendectomy, omenctomy

IMT, G1

GP

PEB*3

NA

YES

Alive 16 months

2

25

98.9

22

USO, Peritonectomies, Omenctomy, lymphadenectomy

MT

GP, Nodal, gliomatosis

NO

+

YES

Alive 3 months

3

16

340.4

20

USO, Peritonectomies, Omenctomy, lymphadenectomy

IMT, G2

GP, Nodal, gliomatosis

PEB*6

+

YES

Alive 68 months

4

18

171.7

14

cystectomy

IMT, G2

NA

PEB*3

NA

YES

Alive 38 months

5

23

NA

11

cystectomy

IMT, G2

NA

NO

NA

YES

Alive 61 months

6

22

381.1

25

USO, Peritonectomies, Omenctomy, lymphadenectomy

IMT, G1

GP, Nodal, gliomatosis

NO

+

YES

Alive 60 months

7

15

673.5

23

USO, Peritonectomies, Omenctomy, lymphadenectomy

LOV: IMT, G3, ROV: G1

GP

PEB*2 PVB*2 PV*2

NA

NO

Alive 97 months

8

17

238.7

30

USO, Peritonectomies, Omenctomy, Lymphadenectomy, Appendectomy

IMT, G3

GP, Nodal, gliomatosis

PEB*4

NA

YES

Alive 144 months

  1. GFAP glial fibrillary acidic protein, GP gliomatosis peritonei, IMT immature teratoma, MT mature teratoma, NA not available, USO unilateral salpingo-oophorectomy, PEB bleomycin, etoposide, cisplatin, PVB bleomycin, vincristine,cisplatin, PV vincristine,cisplatin